If you have read this far into a headline about ketamine therapy, there is a decent chance you are rolling your eyes. That is fine. This FAQ is for Midwesterners who are skeptical of ketamine for depression and want straight answers about the alternatives, especially the ones that do not involve any medication at all.
Our answers lean on two things: a summer poll we funded, answered by 443 Midwest adults in ten states, plus the public record on each option. The poll numbers are final, drawn from the validated responses. Nothing here is medical advice.
Am I unusual for being skeptical of ketamine therapy?
No. We tested a single phrase on our survey panel, ketamine therapy for depression or PTSD, and 21 percent reacted with skepticism. A further 9 percent answered negatively. The biggest bucket, at 34 percent, was cautious but open, and that is a kind of reservation too. Just 18 percent called themselves hopeful or curious.
Do a lot of people want a treatment without drugs?
Yes, by a wide margin. Sixty-four percent of respondents told us a drug-free option mattered. What surprised us was how few knew about the main one: just 25 percent were familiar with TMS. Just over half the sample fell into one telling group, people unfamiliar with TMS who still cared about avoiding drugs.
One limit matters here. These are figures for everyone who answered; this piece does not split out how the skeptics answered on TMS.
What is TMS, and is it legitimate?
TMS stands for transcranial magnetic stimulation. A coil held against the scalp sends magnetic pulses into an area of the brain tied to mood, while you sit in a chair fully awake, with no anesthesia and no medication. TMS devices hold FDA clearance for adult major depression when antidepressants have fallen short.
"Cleared" is the term for the FDA's review pathway for many medical devices, which differs from the "approved" used for drugs. It is a real regulatory review. TMS is widely used in mainstream psychiatry. Like every depression treatment, it works well for some people and not for others.
What is the catch with TMS?
Time. For a skeptic weighing it, the real cost is showing up on most weekdays, several weeks running. In the rural Midwest, where the nearest provider may be in another county or a larger city, that schedule can be a serious obstacle.
My worry about ketamine is addiction. Is that fair?
It is a fair question to raise with a clinician. Ketamine and esketamine are controlled substances with potential for misuse. That is part of why esketamine, sold as Spravato, is only given at certified healthcare sites under a restricted program. You use the nasal spray in the clinic, staff watch you for a minimum of two hours, and no doses go home with you. Driving waits until the following day. Brain Recovery Centers explains the supervised Spravato visit and its safety rules in more detail.
At-home ketamine, often prescribed through telehealth, does not have those same guardrails. IV ketamine for depression is given in clinics but is off-label. If your concern is misuse, those distinctions are worth understanding, whatever you decide.
Is TMS addictive?
TMS involves no medication, so there is no drug to become dependent on. That is one reason some people who are skeptical of ketamine find it appealing.
Are there other drug-free options besides TMS?
Yes. Talk therapy, including cognitive behavioral therapy, has a long track record for depression without any medication, and trauma-focused therapies are a first-line choice for PTSD. Many therapists see clients over video, a real help in Midwest counties with few in-person offices.
How do I know FDA status is being described honestly?
Ask directly. For any treatment, you can ask: "What is this approved or cleared for, and is my use on-label?" Many people in our survey care about the answer. For 59 percent of respondents, FDA approval ranked as a deciding or big factor before trying something new. A trustworthy provider will give you a precise answer rather than a vague reassurance.
Will insurance cover TMS?
Often, but usually after prior authorization. Plans commonly want documentation that you tried antidepressant medication without enough improvement. Call the number on your card before you commit.
Plenty of people put coverage first. Asked for the two provider traits they care about most, 85 percent of our respondents put insurance on the list, and 65 percent said coverage could decide, or weigh heavily on, whether they try a treatment at all.
I'm on Medicaid. Does that change anything?
It means you should call your state Medicaid plan and ask about TMS coverage and in-network providers. You would be in good company: 37 percent of our respondents reported Medicaid, close behind the 39 percent who reported commercial plans. Rules vary by state, so the answer in Iowa may differ from the answer in Kansas or Ohio.
Where does a skeptic start the conversation?
For most people, their own doctor. A doctor's recommendation would move 74 percent of our respondents to try it, and 56 percent named primary care as the place they would start. If your doctor is not familiar with TMS, ask for a psychiatry referral.
A simple opener: "I'm skeptical about ketamine. Could TMS or therapy be a better fit for me?"
Should I stop my current medication?
Not without your prescriber. Stopping abruptly can bring on withdrawal and worsen depression. Many people begin TMS or therapy while staying on medication.
What if none of it sounds right to me?
Then say that, too. Skepticism is a reason to ask more questions, not a reason to go without care. A clinician who knows your history can help you weigh the options honestly.
If thoughts of suicide are part of this for you, set these decisions aside for now and reach a person tonight: skeptics included. The Suicide and Crisis Lifeline sits behind three digits, 988, for a text or a phone call from any Midwest town.
Methodology
Pollfish recruited respondents from its consumer panel for questionnaire 395586438, closed June 23, 2026. We kept 443 finished interviews with people 18 to 64 from Ohio, Kansas, Minnesota, Iowa, Oklahoma, Missouri, Indiana, Nebraska, Wisconsin and Illinois, all screened for consent up front. On items allowing several answers, each figure is the share of all respondents who chose it. The figures come from Pollfish's final, validated export. Our publisher ordered this research and covered its cost.